Introduction: Possession of the apolipoprotein E (APOE) 4 allele advances amyloid (A ) deposition and symptomatic onset of Alzheimer's disease (AD), whereas its effect on the rate of cognitive decline remained controversial. We examined the effects of APOE 4 allele on cognition in biomarker-confirmed late mild cognitive impairment (LMCI) and mild AD subjects in the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) and North American ADNI (NA-ADNI). Methods: The "early AD" (ie, combined LMCI and mild AD) cohort of 649 subjects from J-ADNI and NA-ADNI were selected based on positivity of A confirmed by amyloid positron emission tomography (PET) or cerebrospinal fluid testing. The rates of cognitive decline in the Mini Mental State Examination (MMSE), the Clinical Dementia Rating Sum of Boxes (CDR-SB), and the Alzheimer's Disease Assessment Scale-cognitive subscale 13 (ADAS-Cog) from baseline were examined using mixed-effects model. The effect of 4 on time to conversion to dementia was also analyzed in LMCI using the Kaplan-Meier estimator and log-rank test.
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‡ The full membership of the Japanese ADNI investigators is listed at: https://humandbs. biosciencedbc.jp/en/hum0043-j-adni-authors. 4 carriers and 4 non-carriers. In 4-positive mild AD, the rates of decline in MMSE (P = .003) and CDR-SB (P = .0071) were slower than those in 4 non-carriers.
DISCUSSION:
The APOE 4 allele had little effect on the rates of cognitive decline in the overall biomarker-confirmed early AD, regardless of region and number of 4 alleles, with a slight variability in different clinical stages, the 4 allele being slightly accelerative in LMCI, while decelerative in mild AD. gene is a strong genetic risk factor for the development of AD. Among the three genetic polymorphisms of the human APOE gene causing variation in two amino acid residues, that is, 2, 3, and 4, 3 possession of one or two 4 alleles increases the risk of developing AD by ∼3 to 4 and >10 times, respectively. [4] [5] [6] [7] Furthermore, carriage of one 4 allele is estimated to advance the symptomatic onset of AD by ∼10 years. 8, 9 In contrast to the well-established effects of the 4 allele on the onset age of AD, it is controversial whether 4 allele affects the speed of cognitive decline after the symptomatic onset. Some studies have suggested the accelerating effects of the 4 allele on the progression rate of AD: The cognitive decline in 4 homozygotes has been reported to progress faster compared with 4 heterozygotes 10 ; a meta-analysis study showed that the 4 allele is one of the significant risk factors for rapid cognitive decline in AD. 11 Furthermore, the rates of decrease in the hippocampal volume of patients with AD were shown to be greater in 4 carriers compared with those in non-4 carriers, suggesting that carriage of 4 allele potentially accelerates the progression of neurodegeneration in AD. 7, 12 In sharp contrast, other studies have suggested that the 4 carriage does not affect the rate of symptomatic progression in AD, 13 or even may slow it down. 14, 15 Of interest, some studies have documented a longer disease duration and less mortality of 4-positive patients with AD, 16, 17 which should, however, be carefully interpreted, because it might reflect the longer life expectancy of 4-positive AD patients resulting from the younger onset.
In view of the needs for earlier intervention into the pathophysiology of AD using mechanism-based therapies, the earlier stages of AD are being highlighted. Clinically, mild cognitive impairment (MCI) is defined as a stage between the cognitively normal stage and dementia, 18 and amnesic MCI has been highlighted as a state that exhibits high likelihood of the prodromal stage of AD (MCI due to AD) with A pathology. 19 Carriage of the 4 allele also has been shown to increase the risk of development of MCI. 20, 21 Although the effects of the 4 allele on the progression rate of MCI have not been established yet, some studies have suggested that 4-positive MCI individuals show faster cognitive deterioration, higher rate of conversion to dementia, and faster brain structural changes than the 4-negative individuals. [22] [23] [24] Statistical simulation based on 19 clinical studies has suggested that possession of the 4 allele could slightly accelerate the rate of progression of MCI and AD dementia, although the effect was small. 25 However, previous clinical studies on MCI and AD, in which the diagnosis was not necessarily based on amyloid biomarkers, have been inaccurate in the diagnosis of the early stages of AD. Amyloid positron emission tomography (PET) data in recent phase 3 trials of solanezumab showed that ∼22% of subjects diagnosed as mild AD by clinical criteria did not show evidence of amyloid accumulation. 26 Furthermore, a number of recent clinical trials of disease-modifying therapies for AD target "early AD," combining MCI due to AD (prodromal AD) and mild AD as a single continuous entity. Especially, in the recent phase 2 trial of an anti-A protofibril antibody BAN2401 on early AD participants, the restriction of enrollment of 4 carriers in the highestdose, active-drug arm but not in the placebo group, raised a question if the observed significant effects of the antibody treatment were due in part to the difference in the rates of progression in cognitive decline between 4 carriers and non-carriers. 27 This prompted us to examine the effects of the 4 allele on the progression rate of early AD population with biomarker confirmation of A pathology.
In this present study, we aimed at elucidating the impacts of and can be compared and integrated because they were conducted with nearly identical protocols. 28 We further analyzed the regional difference, allele-number dependency, and disease-stage specificity of the effects of 4 alleles on the progression rate of early AD.
METHODS

Sample datasets
The data set of the J-ADNI (Research ID: hum0043.v1, 2016) was obtained from the National Bioscience Database Center (Tokyo, Japan)
with approval from its data access committee (https://humandbs. biosciencedbc.jp/en/hum0043-v1). Entire data were downloaded on October 11, 2017. The inclusion/exclusion criteria of LMCI and AD in J-ADNI are described in a previous report. 28 Briefly, the age of participants must be between 60 and 85 years. LMCI and AD subjects must have memory complaints by subject or study partner that is verified 18, 24, and 36 months for LMCI subjects and at 6, 12, and 24 months for mild AD subjects and early AD subjects. The data after those time points and one data point at 18 months in NA-ADNI were not used for analyses, in order to ensure comparability and consistency between NA-ADNI and J-ADNI. We analyzed age when subjects are diagnosed at baseline visit (age at diagnosis) instead of age at onset, because ADNI study does not collect age when symptoms start.
Assessments and variables analyzed
In the J-ADNI data set, positivity of A accumulation was defined as the standardized uptake value ratio (SUVR) >1.5 in 11 C-Pittsburgh
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• The region of the population and the number of 4 alleles did not affect the speed of cognitive decline. <333 pg/mL. 28, 29 In the NA-ADNI data set, positivity of A accumulation was defined as an SUVR >1.5 in 11 C-PiB PET, SUVR >1.11 in AV45 (florbetapir)-PET, or CSF A 42 <192 pg/mL. 30, 31 The amyloid status of subjects was determined to be positive when at least either of the PET or CSF results at baseline were positive. Subjects who showed contradictory results in PET and CSF tests were included in the A -positive group.
Statistical analyses
The distribution of categorical and continuous variables between groups was compared by using chi-square test and t test, respectively.
The 
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RESULTS
APOE 4 carriage does not influence the rate of cognitive decline in early AD
We selected 74 LMCI and 70 mild AD subjects from the J-ADNI cohort, and 274 LMCI and 231 AD subjects from the NA-ADNI cohort, based on the A positivity verified by CSF A 42 Figure 1 . We compared the slopes of decline in MMSE, CDR, and ADAS-Cog between 4 carriers and non-carriers using a mixed-effects model, and found that the rates of decline in the above three cognitive scales were not significantly different between 4 carriers and non-carriers, suggesting that the carriage of 4 alleles does not affect the rate of progression after the symptomatic onset in early AD (Table 2A) . To see the effects of regional difference, we compared the slopes of decline in 4 carriers and noncarriers separately in the J-ADNI and NA-ADNI data sets. No significant differences were observed in the slope of decline between 4 carriers and non-carriers in J-ADNI or NA-ADNI (Table 2B ), suggesting the lack of regional differences in the effect of the 4 alleles on the progression rate in early AD. Furthermore, we compared the speed of cognitive decline among the 4 non-carriers (0), heterozygotes (1), or homozygotes (2) of 4 alleles, to see if there is a gene dosage effect of 4 alleles on the rate of progression. The progression rates of cognitive decline in heterozygotes and homozygotes were not significantly different from those in 4 non-carriers, suggesting that the number of the 4 alleles had little effect on the symptomatic progression in early AD (Table 2C) .
Taken together, the APOE 4 carriage did not affect the rate of progression in cognitive deterioration in early AD, regardless of the regional difference or the gene dosage of 4 alleles.
Differential effects of APOE 4 carriage on the rate of disease progression in LMCI and mild AD
To examine the effects of the 4 allele on the rate of disease progression in different disease stages, we separately analyzed the data in Carriers showed almost the same progression rates as non-carriers, except for a small but significantly faster cognitive decline in MMSE (P = .0282) ( Figure 2A and Table 3A ). We then asked whether carriage of 4 affects the time to conversion to dementia, another indicator of cognitive decline of LMCI. Time to conversion of 4 carriers and noncarriers were shown as the Kaplan-Meier plots (Figure 3 ), suggesting that carriage of APOE 4 may slightly accelerate the progression of LMCI, but the association was not statistically significant (log-rank test P = .1623).
Finally, we analyzed the rate of progression in 301 AD subjects, including 216 4 carriers and 85 non-carriers. The demographics of 4 carriers and non-carriers in the AD cohort were not significantly different in most variables analyzed, except for a higher frequency of having family history of the mother (P = .0174) ( Table 1B ). The 2-year longitudinal changes in MMSE, CDR, and ADAS-Cog in mild AD ( Figure 2B) showed that 4-positive mild AD patients showed a significantly slower cognitive decline in MMSE and CDR (P = .003 in MMSE and P = .0071 in CDR) in contrast to LMCI, suggesting that the 4 alleles decelerate the progression of cognitive decline in mild AD (Table 3B) . P-values were calculated by chi-square analysis for categorical data or t test for numerical data. Subjects included in the analysis have evidence of increased brain amyloid confirmed by biomarkers. AD, Alzheimer's disease; ADAS-Cog, Alzheimer's disease assessment scale-cognitive subscale, CDR-SB, clinical dementia rating sum of boxes; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; MMSE, the mini-mental state examination; PET, positron emission tomography; SUVR, standardized uptake value ratio. 
Interaction of time and presence/absence of APOE 4 allele (difference of decline between 4 presence and absence groups per month) 95% CI P-value
DISCUSSION
Our present study showed that the APOE 4 allele does not affect the The effects of the 4 alleles on the progression rate were different between LMCI and mild AD; the decline was slightly faster in 4 carriers than in non-carriers in LMCI, whereas slower in 4 carriers than in non-carriers. The levels of CSF p-tau and total tau, markers of tau-related neurodegeneration, 35 were significantly higher in the 4 carriers than non-carriers in LMCI subjects, raising the possibility that 4-positive LMCI subjects had more advanced pathology compared with the non-carriers; in contrast, CSF levels of p-tau and total tau were similar between 4 carriers and non-carriers in mild AD. These findings may suggest that the 4 allele accelerates tau-mediated neurodegeneration in the LMCI stage, but no longer in the mild dementia stage. Previous studies on the effects of ApoE 4 alleles in cognitively normal individuals suggested that 4 contributes to lower cognitive performance and faster progression of cognitive decline. 36, 37 It has also been shown that the accelerating effect of 4 on cognitive decline was observed in A -positive cognitive normal individuals, but not in A negatives. 38 Taken together, our results suggest that the 4 allele may contribute to neurodegeneration and associated cognitive decline in relatively earlier stages of AD pathophysiology, ranging from cognitively normal to amyloid-positive MCI stages.
Previous clinical studies, including ADNIs, have shown a strong association between carriage of 4 alleles and positive amyloid biomarkers in cognitive normal, MCI, and dementia. 28, 39, 40 Experimental studies in mice models of AD also have suggested that the APOE 4 alleles affect the biological process of A accumulation to increase its deposition. 41 Although at least one study suggested the effects of APOE 4 on tau-mediated neurodegeneration, 42 our results may be consistent with the view that the APOE 4 alleles do not directly affect the process of neurodegeneration including the tau pathology, the latter being more directly linked to the cognitive decline.
There are a couple of limitations in our study. First, the observation period of our analyses was limited to 2 to 3 years, which might have characterized a limited duration of the early stages of AD, although we believe that our data might have implications in the interpretation of results in clinical trials at the early AD stage, which usually have a maximum follow-up of 2 years. Second, the combined analysis of the J-ADNI and NA-ADNI data, which exhibited a couple of minor differences, 28 might have caused some inconsistencies; however, the impact of merging these two cohorts should be minor, because (1) we included data source as a fixed effect in the mixed-effects models and (2) the analyses separately performed in J-ADNI and NA-ADNI drew almost the same conclusions. Finally, our study focusing on the composite cognitive battery may have missed the differential effects of 4 on specific cognitive domains; considering the previous report suggesting that 4 might specifically affect the episodic memory, 43 further analysis on the domain-specific effects will resolve the problem. 
